Search results
Results from the WOW.Com Content Network
Genentech, Inc. is an American biotechnology corporation headquartered in South San Francisco, California, wholly owned by the Swiss multinational pharmaceutical company, the Roche Group. It became an independent subsidiary of Roche in 2009. Genentech Research and Early Development operates as an independent center within Roche. [6]
The company owns the American biotechnology company Genentech, which is a wholly owned independent subsidiary, and the Japanese biotechnology company Chugai Pharmaceuticals, as well as the United States–based companies Ventana and Foundation Medicine. Roche's revenues during fiscal year 2020, were 58.32 billion Swiss francs.
Autogene cevumeran is an investigational mRNA vaccine being developed jointly by BioNTech and Genentech as an adjuvant therapy in cancer treatment to prevent cancer recurrence following surgery. [ 1 ] [ 2 ] [ 3 ]
The Roche/Genentech oncology pipeline includes 40 investigational cancer medicines being studied in 600 clinical trials across a dozen types of cancer. ... Genentech is a leading biotechnology ...
Genentech previously said the use of the drug in the indication accounts for a fraction of its overall revenue. The U.S. Food and Drug Administration had granted accelerated approval to Gavreto in ...
The company's flagship product was Interleukin-2 (IL-2), an important modifier of the immune system. In the early 1980s, an intense competition to clone the gene for IL-2 was underway among Cetus, Genentech, Immunex, and the Japanese researcher, Tadatsugu Taniguchi, and in 1982 Taniguchi was the first to succeed.
Genentech Announces FDA Approval of Tamiflu for the Treatment of Influenza in Infants -- First Medicine Approved to Treat Influenza in Infants Two Weeks of Age and Older -- SOUTH SAN FRANCISCO ...
Galena Biopharma, Inc. (originally RXi Pharmaceuticals) was a publicly traded pharmaceutical company based in San Ramon, California. The company was founded in Worcester, Massachusetts. In 2011, it moved to Oregon, [1] [2] and in 2015 moved to San Ramon, California. [3] Mark Schwartz was the company's president and chief executive officer.